person · Reporting owner
WARRINGTON KENNETH HOWARD JR
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioStem Technologies, Inc.BSEM · Entity 7054 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioStem Technologies, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,928 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 1,694 · Balance 33,928 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,773 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 1,694 · Balance 6,773 F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-03-29 | Direct | 7,462 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 7,462 F1: These options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These options are fully vested and exercisable.
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 1,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394390 · ownership.xml · derivative · entry 3 WARRINGTON KENNETH HOWARD JR · CIK 0002147208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,773 Underlying: Common Stock · 1,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). F3 · derivative.expiration_date: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 1,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394390 · ownership.xml · nonDerivative · entry 1 WARRINGTON KENNETH HOWARD JR · CIK 0002147208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 16:15 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 5,094 | $0.00 | $0.00 |
DisclosureSEC source: 0002147208-26-000004 · ownership.xml · derivative · entry 4 WARRINGTON KENNETH HOWARD JR · CIK 0002147208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: These restricted stock units vested quarterly over the year following the grant date (August 27, 2025). F4 · derivative.expiration_date: These restricted stock units vested quarterly over the year following the grant date (August 27, 2025). Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 16:15 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 5,094 | $0.00 | $0.00 |
DisclosureSEC source: 0002147208-26-000004 · ownership.xml · nonDerivative · entry 1 WARRINGTON KENNETH HOWARD JR · CIK 0002147208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.